CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 175.545 AUD -0.91%
Market Cap: 85.2B AUD

Operating Margin
CSL Ltd

26.4%
Current
26%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
26.4%
=
Operating Profit
4.1B
/
Revenue
15.6B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
CSL Ltd
ASX:CSL
85.8B AUD
26%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395.1B USD
33%
US
Amgen Inc
NASDAQ:AMGN
174.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
148.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD
28%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD
8%
NL
argenx SE
XBRU:ARGX
44.3B EUR
22%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
No Stocks Found

CSL Ltd
Glance View

In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.

CSL Intrinsic Value
226.45 AUD
Undervaluation 22%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
26.4%
=
Operating Profit
4.1B
/
Revenue
15.6B
What is the Operating Margin of CSL Ltd?

Based on CSL Ltd's most recent financial statements, the company has Operating Margin of 26.4%.

Back to Top